A Researcher from the Department of Chemistry Obtains a Patent on a New Derivative of Cephalexin-Substituted Maleamide as an Anticancer and Antibacterial
A Researcher from the Department of Chemistry Obtains a Patent on a New Derivative of Cephalexin-Substituted Maleamide as an Anticancer and Antibacterial
Patent the Invention
The Lecturer (Asst. Dr. Ammar Abdul Hussein al-Karawi) from the Faculty of education for pure sciences\ department of Chemistry at Karbala University has a patent from the Central Organization for Standardization and quality control to enable him to manufacture a new pharmaceutical compound. The patent included the preparation of a pharmaceutical derivative of benzoic malimide compensated with cephalexin, and the new pharmacological compound was characterized by an antibacterial effectiveness that exceeds the effectiveness of the original drug with a weakening and almost zero cytotoxicity and a very high ability to inhibit the growth of cancer cells and with a concentration corresponding to half inhibition of (IC50 = 6.22) micrograms / milliliters. The patent also consisted of two parts, the first is the manufacture of a compound of 4-malimido benzoic acid as a carrier medium and as a lipophilic group containing an active double sphincter that acts as a receptor for nucleophilic addition (Michael addition), which targets the sulfur group of the amino acid cysteine and then binds it to the drug cephalexin. The patent aimed to prepare a drug with dual bio-effectiveness for the treatment of various infections, especially those accompanying cancers. It is worth mentioning that the researcher has Published 6 scientific papers in international publications such as scopes.
A Researcher from the Department of Chemistry Obtains a Patent on a New Derivative of Cephalexin-Substituted Maleamide as an Anticancer and Antibacterial
The Lecturer (Asst. Dr. Ammar Abdul Hussein al-Karawi) from the Faculty of education for pure sciences\ department of Chemistry at Karbala University has a patent from the Central Organization for Standardization and quality control to enable him to manufacture a new pharmaceutical compound. The patent included the preparation of a pharmaceutical derivative of benzoic malimide compensated with cephalexin, and the new pharmacological compound was characterized by an antibacterial effectiveness that exceeds the effectiveness of the original drug with a weakening and almost zero cytotoxicity and a very high ability to inhibit the growth of cancer cells and with a concentration corresponding to half inhibition of (IC50 = 6.22) micrograms / milliliters. The patent also consisted of two parts, the first is the manufacture of a compound of 4-malimido benzoic acid as a carrier medium and as a lipophilic group containing an active double sphincter that acts as a receptor for nucleophilic addition (Michael addition), which targets the sulfur group of the amino acid cysteine and then binds it to the drug cephalexin. The patent aimed to prepare a drug with dual bio-effectiveness for the treatment of various infections, especially those accompanying cancers. It is worth mentioning that the researcher has Published 6 scientific papers in international publications such as scopes.
